文献速递特殊人群用药抗栓抗凝管理治疗药物监测与药物基因组学

模型模拟支持儿童ALL/LL接受门冬酰胺酶治疗时阿哌沙班剂量

Modeling and Simulation to Inform Apixaban Dosing in Pediatrics With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated With Asparaginase.
PubMed 文献 · Clin Pharmacol Ther · 2025-04-29

该分析基于PREVAPIX III期研究数据,建立更新的二室群体药代动力学模型,描述阿哌沙班在儿童ALL或LL接受门冬酰胺酶治疗中的药代动力学变异。ALL/LL患者类型是表观中央分布容积和一级吸收速率的显著协变量,儿童ALL/LL患者Ka较成人低52.4%、较其他VTE风险儿童低81.1%,Vc/F较成人低43.1%。更新模型模拟确认按体重分层的固定剂量方案在28天至<18岁ALL/LL儿童中达到目标暴露,并建立抗FXa活性与阿哌沙班浓度的PK/PD关系。

要点

  • 儿童ALL/LL患者阿哌沙班Ka较成人低52.4%,Vc/F较成人低43.1%。
  • ALL/LL患者Ka较其他VTE风险儿童低81.1%。
  • 按体重分层固定剂量方案在28天至<18岁ALL/LL儿童中达到目标暴露。

核心结论

  • 阿哌沙班可能是儿童ALL或LL患者预防VTE的潜在抗栓选择。

研究设计与样本

  • 基于PREVAPIX III期研究PK数据建立更新的二室群体药代动力学模型。
  • 模拟对象为28天至<18岁ALL或LL儿童,评估按体重分层固定剂量方案的目标暴露。
  • 采用线性回归模型分析抗FXa活性与阿哌沙班浓度的PK/PD关系。

主要发现

  • ALL或LL患者类型是表观中央分布容积(Vc/F)和一级吸收速率(Ka)的显著协变量。
  • 9个月至<18岁ALL/LL儿童Ka较成人低52.4%。
  • 9个月至<18岁ALL/LL儿童Ka较其他VTE风险儿童低81.1%。
  • 儿童ALL/LL患者Vc/F较成人低43.1%。
  • 按体重分层固定剂量方案在28天至<18岁ALL/LL儿童中达到目标暴露。

临床怎么用

  • 临床可参考按体重分层的阿哌沙班固定剂量方案,用于28天至<18岁ALL/LL儿童的目标暴露。
  • 抗FXa活性与阿哌沙班浓度的PK/PD关系可用于支持该人群的暴露评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Apixaban could be a potential treatment option for the prevention of venous thromboembolism (VTE) in children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). This analysis describes an updated two-compartment population pharmacokinetic (PPK) model that characterizes the PK variability of apixaban in pediatric patients with ALL or LL treated with asparaginase using PK data from a phase III study (PREVAPIX). Patient type of ALL or LL was found to be a significant covariate on the apparent central volume of distribution (Vc/F) and first-order absorption rate (Ka). Pediatric patients (aged 9 months to < 18 years) with ALL or LL had a 52.4% lower Ka compared with adults; this was 81.1% lower than other pediatric patients (9 months to < 18 years) at risk of VTE. Apixaban Vc/F was estimated to be 43.1% lower in pediatric patients compared with adult patients. The updated PPK model was used to simulate and confirm apixaban fixed-dose by weight-tiered regimen-achieved target exposures in pediatric patients (aged 28 days to < 18 years) with ALL or LL. In addition, a PK/pharmacodynamic (PD) analysis was performed using a linear regression model to characterize the relationship between anti-FXa activity (AXA) and apixaban concentration in pediatric patients with ALL or LL. The characterization of apixaban PK and PK/PD in this analysis contributes to evidence that apixaban could be a potential antithrombotic option in pediatric patients.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jarugula P, Ajavon-Hartmann T, Obianom O, et al. Modeling and Simulation to Inform Apixaban Dosing in Pediatrics With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated With Asparaginase. Clin Pharmacol Ther. 2025. PMID: 40302153. doi:10.1002/cpt.3616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。